Related Experiment Video
Updated: Apr 4, 2026
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
[Novel biomarkers in renal cell carcinoma. Identification and functional characterization]
1Pathologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Deutschland. stephan.goeppinger@med.uni-heidelberg.de.
Abstract:
Due to advanced imaging techniques, renal cell carcinoma (RCC) is now identified earlier, often in localized stages. As a result, nephron-sparing surgical resection is possible in most cases. The development of new targeted therapies has changed the way metastatic RCC is treated. Despite this positive trend with improved survival rates and expanding treatment options, reliable biomarkers for better predicting disease course are lacking. These are urgently needed to enable personalized therapy based on the treatment-associated risks, the presence of comorbidities, and molecular tumor characteristics. We were able to show that proteins with a regulatory influence on apoptotic signal cascades represent not only promising prognostic markers, but also interesting targets for new therapeutic approaches. Furthermore, our data demonstrate that molecular tests are necessary to correctly classify a RCC with Xp11.2 translocation, since in addition to translocation, amplification can also result in TFE3 activation. Translational research with RCC biomarker identification and establishment, as well as molecular characterization and subtyping of RCCs is required to guide therapeutic decisions and enable personalized medicine in RCC patients.
Insights
Identifying reliable biomarkers is crucial for personalized renal cell carcinoma (RCC) treatment. Proteins regulating apoptotic pathways and molecular tests for Xp11.2 translocation show promise for improved patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Translational Research
Background:
- Advanced imaging detects renal cell carcinoma (RCC) earlier, enabling nephron-sparing surgery.
- Targeted therapies have improved metastatic RCC treatment and survival rates.
- A lack of reliable biomarkers hinders personalized therapy for RCC patients.
Purpose of the Study:
- To identify novel prognostic markers and therapeutic targets for renal cell carcinoma (RCC).
- To emphasize the need for molecular tests in classifying specific RCC subtypes.
- To advocate for translational research in RCC biomarker discovery and molecular subtyping.
Main Methods:
- Analysis of proteins involved in apoptotic signal cascades.
- Molecular testing to identify Xp11.2 translocations and TFE3 activation.
- Evaluation of biomarkers for predicting disease course and guiding therapy.
Main Results:
- Proteins regulating apoptotic pathways show potential as prognostic markers and therapeutic targets.
- Molecular tests are essential for accurate classification of RCC with Xp11.2 translocation.
- TFE3 activation can result from translocation or amplification in RCC.
Conclusions:
- Biomarkers, particularly those related to apoptosis, are vital for personalized RCC treatment.
- Molecular characterization is necessary for accurate RCC subtyping and therapeutic decision-making.
- Translational research is key to advancing personalized medicine in renal cell carcinoma.
